今日盘中，港股中国抗体-B（03681）股价大涨32.68%，引发市场广泛关注。截至13:51，该股报价2.07港元，成交额已超过3300万港元。
消息面上，中国抗体近日宣布完成发行合共1.13亿股新股。公司此前公告称，拟向26名认购人发行约1.128亿股认购股份，占经扩大已发行股份约9.37%，每股认购价1.10港元，募资约1.24亿港元。这一举措有效增强了公司的资金实力，为未来发展提供了有力支持。
据悉，此次配售所得款项将主要用于以下几个方面：45%用于SM17的研发及临床项目，特别是在中国进行特应性皮炎的皮下桥接研究及二期临床研究；20%用于新候选药物的临床前研究、临床试验及相关准备工作，以实现产品组合多元化；35%用作一般营运资金。市场分析认为，此次融资将加速中国抗体的新药研发进程，有望提升公司的长期竞争力，因此引发了投资者的积极反应，推动股价大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.